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Abstract 
Background:  Angiotensin  converting  enzyme  (ACE)  is  a  key  component  in  the  renin 
angiotensin aldosterone system (RAAS) which regulates blood pressure. As the over expression 
of RAAS is associated with vascular hypertension, ACE inhibition has become a major target 
control for hypertension. The research on potential ACE inhibitors is expanding broadly and 
most are focused on natural product derivatives such as peptides, polyphenolics, and terpenes. 
Plant  polyphenolics  are  antioxidant  molecules  with  various  beneficial  pharmacological 
properties.  The current study is focused on investigating and reviewing the ACE inhibitory 
property  of  fruit  flavonoids.  An  apple  skin  extract  (ASE)  rich  in  flavonoids,  the  major 
constituents of the extract and their selected metabolites were assessed for the ACE inhibitory 
property in vitro. It is important to investigate the metabolites along with the flavonoids as they 
are the constituents active inside the human body.  
 
Objective: To investigate whether flavonoids, flavonoid rich apple extracts and their metabolites 
could inhibit ACE in vitro. 
 
Method: The samples were incubated with sodium borate buffer (30 µL, pH 8.3), 150 µL of 
substrate (Hip-His-Liu) and ACE (30 µL) at 37 
oC for 1 h. The reaction was stopped by addition 
of 150 µL of 0.3M NaOH. The enzyme cleaved substrate was detected by making a fluorimetric 
adduct by adding 100 µL of o-phthaladehyde for 10 min at room temperature. Reaction was 
stopped by adding 50 µL of 3M HCl. Fluorescence was measured by using a FluoStar Optima 
plate reader at excitation of 350 nm and emission of 500 nm.  
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Results: The extract and the compounds showed a concentration dependant enzyme inhibition. 
Increasing concentrations from 0.001 ppm to 100 ppm of ASE showed an increment of 29% to 
64%  ACE  inhibition.  The  IC50  (concentration  of  test  compound  which  gives  50%  enzyme 
inhibition) values of ASE, quercetin, quercetin-3-glucoside, quercetin-3-galactoside, cyanidin-3-
galactoside  were  49  µg/mL,  151  µM,  71  µM,  180  µM,  206  µM,  respectively.  The  major 
constituents of the ASE that were tested separately showed effective ACE inhibition. From the 
three metabolites tested, only quercetin-3-glucuronic acid showed concentration dependant ACE 
inhibition. The ACE inhibition of 0.001 ppm to 100 ppm of quercetin-3-glucuronic was in the 
range of 43% and 75% and the IC50 value was 27 µM.  
 
Conclusion: The results demonstrated that flavonoids have a potential to inhibit ACE in vitro 
and the inhibitory property varies according to type of sugar moiety attached at C-3 position. The 
results also revealed that the major contributing compounds of ASE for ACE inhibition belong to 
flavonoids. Among the tested compounds, the lowest IC50 value is associated with the quercetin-
3-glucuronic acid, a major in vivo metabolites of quercetin and its glycosides. The results suggest 
that certain dietary flavonoids may possess properties of blood pressure regulation. 
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Background 
Hypertension  is  a  common  progressive  disorder  leading  to  several  chronic  diseases  such  as 
cardiovascular  disease,  stroke,  renal  disease  and  diabetes.  One-quarter  of  the  world's  adult 
population is afflicted by hypertension, and this is likely to increase to 29% by 2025 [1]. Life 
style changes, physical exercise, intake of healthy diets are some common issues associated with 
reducing the risk of hypertension. However, at critical stages drugs are essential. Therefore, it is 
of great importance to discover natural therapeutics for prevention and cure. 
The pathogenesis of hypertension could be due to many reasons. For example, increased 
activity  of  renin  angiotensin  aldosterone  system  (RAAS),  kalikerenin  kinin  system  and 
sympathetic  nervous  system,  and  genetic  influence  are  specified  [2].  Among  them  over 
activation of RAAS (Fig. 1) is significant [3]. Angiotensin converting enzyme (ACE) plays a 
significant role in RAAS, by converting the precursor angiotensin I into angiotensin II which is 
the peptide responsible in triggering blood pressure increasing mechanisms. Therefore, inhibition 
of ACE is a promising way of controlling over expression of RAAS.  
 
ACE  inhibitory  drugs  are  first  class  therapeutics  since  decades.  Captopril
®,  Lisinopril
®, 
Enalpiril
®, and Rampiril
® are some examples for drugs targeted as ACE inhibitors. However, the 
prolong  use  of  the  drugs  could  initiate  adverse  side  effects  like  dizziness,  coughing,  and Functional Foods in Health and Disease 2011; 5:172-188                                                                           Page 174 of 188 
angioneuretic edema [4].  New alternatives have been explored extensively as replacements of 
these drugs. Most of the researches have been targeted at bioactive compounds from natural 
resources. Peptides [5], anthocyanins [6], flavonols [7], triterpenes [8] are some examples. The 
objective of this review is to assess the potential of plant flavonoids to use as ACE inhibitors in 
regulation of hypertension.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1: Renin angiotensin aldosterone system (RAAS) 
 
 
ACE inhibition 
 
ACE 
ACE  is  a  dipeptidyl  carboxypeptidase  with  a  zinc  atom.  The  enzyme  has  a  less  substrate 
specificity in vitro. ACE consists of a single polypeptide chain containing two domains: N and 
C. There are two catalytic sites in each of these domains [9]. The highest concentrations of ACE 
are  present  in  the  lung  capillaries.  As  well,  ACE  is  present  in  renal  proximal  tubules, 
gastrointestinal  tract,  cardiac  tissues  and  brain  tissues  [10].  It  exists  as  a  membrane  bound 
enzyme as well as a circulatory or globular enzyme [9].  
 
Assessment of Enzyme Inhibition 
There  are  number  of  methods  used  in  detection  of  ACE  inhibition.  Among  them  are 
spectrophotometric,  fluorometric,  high-performance  liquid  chromatographic  (HPLC), 
radiochemical and electrophoresis methods [10, 11]. As there is less substrate specificity for 
ACE, several substrates have employed for in vitro enzyme inhibitory studies. Two commonly 
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used  substrates  for  spectrophotometric  and  HPLC  analysis  of  ACE  inhibitory  activity  are 
hippuryl-L-histidyl-L-leucine  (HHL)  and  N-(3-[2-furyl]acryloyl-phenylala  glycy  L  glycine 
(FAPGG) [12, 13]. HHL could be used in fluorescence detection methods of ACE inhibition 
along with fluorescing agents such as o-pthaldehyde [10]. The conversion of internally quenched 
fluorogenic  substrates  are  reported  to  be  very  sensitive  in  detection  of  ACE  inhibition.  o-
Aminobenzoylglycyl-p-nitro-phenylalanylproline  [14]  and  abz-peptidyl-Eddnp  (Abz:  ortho 
amino benzoic acid. Eddnp: 2,4-dinytrophenyl ethylenediamine) are two examples of flurogenic 
substrates [10]. 
 
Natural ACE Inhibitors 
Different  types  of  natural  food  derived  compounds  have  been  investigated  on  their  ACE 
inhibitory properties. Food protein derivatives are a major group of compounds investigated as 
potential ACE inhibitors. Food proteins can be divided into three categories as animal-derived, 
plant-derived and microorganism-derived peptides. Animal-derived category includes peptides 
from milk, meat, fish and eggs [15]. Casein, whey protein hydrolysates from milk, ovokinin from 
eggs are reported to be effective ACE inhibitors in both in vivo and in vitro studies [15, 16]. 
Meat and fish proteins are hydrolyzed using different enzymes like chymases, and the resulting 
fractions are subjected in determining ACE inhibitory properties. Among the fish species used 
for deriving ACE inhibitory peptides are bonito, sardine, salmon, hake and tuna [17, 5]. Plant-
derived peptides have also been identified from different sources including soybean, flaxseed, 
sunflower, rice, and corn [18, 19, 12]. There is less evidence on microorganism-derived peptides. 
Secondary metabolites produced in plants are another group of natural compounds which are 
identified as potential ACE inhibitors. Some terpenoids and polyphenolic compounds including 
flavonoids, hydrolysable tannins, xanthones, procyanidins, caffeolyquinic acid derivatives  are 
found to be effective as natural ACE inhibitors [20, 21]. Most studies have showed that plant 
extracts rich in phytochemicals found to be effective in ACE inhibition. However, identification 
of compounds specifically inhibit ACE is lacking in most of these investigations.  
 
Flavonoids as ACE inhibitors 
Flavonoids are the largest group of polyphenolic compounds found in higher plants [22]. Tea, 
wine, apples, onions, grapes, and oranges are some foods rich in flavonoids. The biosynthesis of 
flavonoids occurs in higher plants through the shikimic acid and malonic acid pathways [23]. 
The common structure of flavonoids is comprised of two phenyl rings (A and C rings) joined 
with three carbons which make a closed pyran ring structure (B ring) (Fig. 2) [24]. Based on the 
structural differences, flavonoids are further subdivided into six sub-groups namely flavanones, 
flavones,  flavonols,  flavan-3-ols,  anthocyanins  and  isoflavones  [24].  The  highly  diverse 
structures of flavonoids show numerous functions in biological systems. In plants, flavonoids 
contribute  to:  insect  attraction  and  repulsion  through  colour  of  leaves,  fruits  and  flowers; 
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etc. [25]. Flavonoids are effective antioxidants in plants as well as in animals [22]. Flavonoids 
are  identified  as  potential  risk  reducing  components  in  the  diet  for  cardiovascular  disease, 
various cancers, neurodegenerative diseases, etc. [25]. For example, quercetin-3-O-glucoside, a 
flavonoid compound ubiquitous in fruits, has shown protective effect on human neuroblastoma 
cells  (SH-SY5Y) against  oxidative stress  by a membrane  injury  recovery mechanism that is 
involved in up-regulation of genes involved in lipid and cholesterol synthesis [26].  
The ability to use flavonoids as ACE inhibitors in regulating blood pressure had been studied 
during the past decades and most of them have proved to be effective in suppressing the activity 
of ACE [6, 7, 27]. The specificity of flavonoid sub-groups in inhibiting ACE would be discussed 
separately. 
 
Anthocyanins 
Anthocyanins are water soluble plant pigments giving rise to red, blue and purple colours of 
fruits and vegetables. In plants, they occur as anthocyanidins (aglycone form, Fig. 2) and then 
conjugate with sugars to form anthocyanins [24]. Anthocyanins have shown ACE inhibition in 
vitro. Delphinidin-3-O-sambubiosides and cyanidin-3-O-sambubiosides isolated from Hibiscus 
(Hibiscus  sabdariffa) extracts  had  inhibited ACE in  a dose dependant  manner [6]. The IC50 
values of anthocyanins  were found to be in  100 to  150 µM  range  (Table 1)  [6]. Similarly, 
cyanidin-3-O-β-glucoside isolated from rose species (Rosa damascene) inhibited ACE in vitro. 
However, other flavonols isolated from rose extract were not effective ACE inhibitors when 
compared  to  cyanidin-3-O-β-glucoside  [27].  Bilberry  (Vaccinium  myrtillus)  extracts  rich  in 
major anthocyanins i.e. cyanidin, delphinidin and malvidin, were investigated on their effect on 
ACE in a human umbilical vein endothelial cell (HUVEC) culture model and the ACE activity 
had  been  significantly  reduced  after  incubation  of  cells  with  bilberry  extracts  [28].  Dietary 
administration  of  anthocyanins-rich  (cyanidin-3-glucosides,  cyanidin-acyl-glucoside  and 
peonidin-acyl-glucoside)  purple  corn,  purple  sweet  potato  and  red  radish  to  spontaneously 
hypertensive  rats  (SHR)  had  decreased  the  systolic  and  mean  blood  pressure  [29].  The 
mechanisms behind the reduction of blood pressure by anthocyanins were reported due to their 
antioxidant  activity,  preservation  of  endothelial  nitric  oxide,  and  prevention  of  serum  lipid 
oxidation but ACE inhibition was not found [29].  
The observed ACE inhibitory activity of anthocyanins in vitro could be explained by the 
metal chelating ability of flavonoids with hydroxyl groups at 3, 5, 7 and 3’, 4’ positions [27, 28]. 
The  planer  structure  of  the  anthocyanin  molecules  also  indicated  to  be  important  in 
metallopeptidase inhibition [6]. In animals, the absorption rate and the corresponding metabolites 
of anthocyanins affect on the enzyme inhibition. However, a strong correlation between ACE 
inhibition in vitro and animal model systems has not been reported.  
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Flavanols have a saturated C-ring with a hydroxyl group at the C-3 position (Fig. 2). They do not 
exist in glycosylated form as the other flavonoids. They can be found in both monomer form 
(catechins) and polymer form (procyanidins) [24]. When ACE was incubated with flavanol rich 
food  extracts  such  as  chocolates,  tea  and  wine,  a  significant  correlation  between  the  ACE 
inhibition  and  the  concentration  of  procyanidin  and  epicatechin  was  observed  [30].  ACE 
inhibition  by  epicatechins  of  cocoa  would  be  a  reason  for  reported  evidence  for  positive 
relationship between dark chocolate consumption and reduced high blood pressure [31]. The four 
major  catechins,  (–)-epicatechin,  (–)-epigallocatechin,  (–)-epicatechingallate  and  (–)-
epigallocatechingallate, isolated from tea had also shown a dose dependant ACE inhibition in a 
HUVEC culture model [32]. Pycnogenol, a procyanidin oligomer, isolated from French maritime 
pine (Pinus maritime) had also reported as an effective mediator for blood pressure regulation 
possibly  by  ACE  inhibition  [33].  These  studies  prove  that  among  flavonoids,  flavanols  and 
procyanidins could also act as potent inhibitors of ACE in vitro.  
The relationship between structure of flavanols and ACE inhibitory properties in vitro 
had been studied [34]. Increasing numbers of epicatechin units in the procyanidins had increased 
the enzyme inhibition [34]. When tested using HUVEC cell cultures, tetramer was the most 
effective enzyme inhibitor compared to dimer and hexamer of procyanidins [34]. The monomers 
of  flavanols  were  found  to  be  absorbed  in  the  small  intestine  [35].  However,  absorption  of 
procyanidins with higher molecular weight has not clearly been reported. Though the tetramers 
were proved to be the most effective in vitro, the dimers are more effective in biological systems 
compared to both tetramers and hexamers [34].  
 
Flavonols 
Flavonols (Fig. 2) are reported to be the most ubiquitous flavonoid sub-group present in 
foods. Quercetin, kaempferol and myricetin are the three types of most common flavonols in our 
diet [24]. ACE inhibitory property of many flavonols has been reported. When a bioassay-guided 
fractionation  of  extract  of  stonecrop  (Sedum  sarmentosum)  was  performed,  five  purified 
flavonols were found to possess ACE inhibitory activity [36] (Table 1). Kaempferol-rich stem 
bark  extracts  of  Cluster  Fig  (Ficus  racemosa)  has  shown  a  dose  dependant  ACE  inhibition 
property in vitro [37]. Based on an ex vivo experiment conducted using aortic tissues of male 
Wistar-Kyoto rats, kaempferol was found to be an effective ACE inhibitor but not resveratrol 
[38], a polyphenolic that is abundant in red wine. The presence of carbonyl group in the pyran 
ring of kaempferol is lacking in resveratrol and this could be a reason for the differences in their 
ACE inhibitory activity. However, when strawberry extracts rich in flavonoids were tested for 
ACE inhibition in vitro, no ACE inhibition was observed [39]. Aqueous extracts of  Gingko 
biloba,  which had  quercetin derivatives  as  the  major flavonoids, had higher  ACE inhibitory 
activity than that of ethanol extracts [40]. The aqueous extracts of red currents (Ribes rubrum L.) 
and black currents (Ribes nigrum L.) exhibited ACE inhibition in vitro but not the extracts of red 
and green gooseberries (Ribes uva-crispa) [41]. The variation of differences in ACE inhibitory Functional Foods in Health and Disease 2011; 5:172-188                                                                           Page 178 of 188 
activity of plant extracts can be due to the presence of type of flavonoids and their concentration 
due  to  genetic  differences  of  plant  materials  and  the  method  of  preparation  of  extracts, 
respectively. 
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Fig. 2: Basic structures of selected major flavonoids 
 
Flavonols  act  as  prominent  antioxidants  in  biological  systems.  Dietary  quercetin 
supplementation at 730 mg/d for 28 d was found to be effective in reducing blood pressure in 
hypertensive patients in a randomized, double-blind, placebo-controlled, crossover study [42]. In 
another  study,  Captopril
®  and  quercetin  treatments  have  been  given  to  male  Wistar  rats 
separately,  whose  hypertensive  responses  were  triggered  by  angiotensin  I  and  bradikinin
® 
injections. Bradykinin is a physiologically active peptide that causes blood vessels to enlarge. 
Both  treatments  triggered  the  hypotensive  responses  significantly  and  quercetin  was  equally 
effective to Captopril when given orally or intravenously [43]. Significant reduction of plasma 
ACE due to quercetin pretreatment (88.7 mol/kg) was reported in this animal study. In contrast, 
chronic treatment of quercetin aglyconee that was given at 10 mg/kg intraperitoneally for 14 ds 
to rats, did not inhibit plasma ACE activity with compared to the control group [44].  
ACE is found to be involved in plasma protein extravasation (PE), which is an important 
component in neurogenic inflammation [45]. It is known that PE can be evoked by substance P 
which is hydrolyzed by ACE. Similar to the action of Captopril, dietary supplementation of 
quercetin can potentiate plasma PE induced by substance P in rat urinary bladder possibly by Functional Foods in Health and Disease 2011; 5:172-188                                                                           Page 179 of 188 
inhibition  of  the  peptidase  which  hydrolyze  substance  P  [46].  From  the  reviewed  literature, 
flavonols showed potential ACE inhibition both in vitro and in vivo. However, since flavonols 
are  known  to  produce  sulfate,  glucuronide  and  methylated  metabolites  in  vivo  [47],  ACE 
inhibition by quercetin metabolites in vitro required further investigation.  
 
Isoflavones 
Isoflavones are unique flavonoids as they exhibit structural similarity to mammalian estrogen 
hormone. They can effectively bind to the estrogen receptors and often called as phytoestrogens 
[48].  Genistein,  daidzein  and  glycetin  are  the  common  isoflavones  present  in  plants  ([24]. 
Among them, genistein is the prominent isoflavone widely investigated on health promoting 
effects.  The  major  isoflavone  in  soybean  is  genistein  [49].  Genistein  has  been  reported  for 
reducing blood pressure in animal models. For example, genistein has decreased NaCl-sensitive 
hypertension in stroke-prone spontaneously hypertensive rats [50]. Genistein dose-dependently 
decreased ACE  gene expression and enzyme activity in  rat  aortic  endothelial cells  (RAEC). 
serum and aorta tissue [51]. However, the exact mechanisms for this modulation were not fully 
understood. Xu and co-workers (2006) found that genistein dose-dependently decreased ACE 
gene expression and enzyme activity in rat aortic endothelial cells (RAEC), serum and aorta 
tissue.  The effect was mediated by estrogen receptor and subsequent activation of the ERK1/2 
signaling pathway in RAEC. In vitro studies showed a concentration dependant ACE inhibition 
by genistein which was confirmed by others [52]. However, the presence of isoflavones in ACE 
inhibitory soybean peptide fractions had not shown any enhanced enzyme inhibitory effect when 
compared with the peptide fractions without isoflavones. Studies had conducted using animal 
models  to  investigate  the  in  vivo  activity  of  isoflavones.  Pretreatment  of  single  intravenous 
injection dose of genistein 25 mg/kg had shown reduced hypertensive responses in hypertensive 
Wistar rats.  The reduced hypertension was associated with significant reduction of ACE activity 
in rat plasma [52]. Another in vivo study had proved that genistein can down regulate the ACE 
producing gene expression by interfering with cell signaling pathways [51].  However, there are 
no related studies on two other soybean isoflavones, daidzein and glycetin, on ACE inhibitory 
effect.  
 
Flavones 
There is less information on ACE inhibitory properties of flavones when compared to the other 
types  of  flavonoids.  However,  extracts  of  Roxb  (Ailanthus  excelsa),  Japanese  cedar 
(Cryptomeria japonica), (H. sabdariffa) and Senecio species (Compositae) which comprise of 
flavones have shown the ACE inhibitory property [21, 53]. The two major flavones of Roxb, 
apigenin and luteolin, have shown a dose dependant enzyme inhibition. Compared to luteolin 
aglyconee, luteolin-7-O-glucoside had shown a reduced enzyme activity comprising to a higher 
IC50 value (Table 1) [21]. The loss of hydroxyl group at 7
th position could be the reason for the 
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cedar has inhibited ACE in vitro and resulted an IC50 value of 16 µg/mL. The extract was rich in 
flavan-3-ols and flavones. The enzyme inhibitory effect would be a  result of the synergistic 
effect of all compounds present in the extract [54]. Crude hydroalcoholic extract rich in flavones 
from H. sabdariffa had shown satisfactory enzyme inhibition on ACE but not elastase, trypsin 
and alpha-chymotrypsin [55]. As all the studies discussed were investigating the effect of plant 
extracts containing flavones, the inhibitory effect could also be due to other constituents of the 
extract. Specific focus on isolated flavone compounds and their ACE inhibitory activity can 
generate valuable information about the flavones with ACE inhibition properties.  
 
Other flavonoids 
Chalcones  are  precursor  molecules  of  the  biosynthetic  pathways  of  flavonoids  [23].  These 
consist of two phenyl rings joined by a three carbon open chain. There are numerous evidences 
on beneficial pharmacological properties of chalcones. Chalcones and their pyrazole derivatives 
inhibited  ACE  in  a  concentration  dependent  manner  in  vitro  [56].  Butein,  a  chalcone, 
supplementation  through  intravenous  injection  has  been  found  to  reduce  the  arterial  blood 
pressure in anesthetized normotensive rats [20]. The ACE activities were found to be decreased 
in a dose dependant manner; however, the value of butein seems to be significantly greater than 
other flavonoids (Table 1).  
 
Structurally modified flavonoids 
In general, most of the phytochemicals including flavonoids are shown more effective beneficial 
pharmacological properties in vitro than in vivo. This could be due to several reasons including 
low bioavailability, lack of stability, poor membrane penetration, lack of site specific distribution 
and rapid elimination of these flavonoids [57]. Introducing structural modifications to flavonoids 
were found to be effective in enhancing some biological functionality of parent flavonoids. The 
methylated form of tea catechins had been found as effective ACE inhibitors. The methylated 
molecule epigallocatechin-3-O-(3-O-methyl)gallate had shown higher inhibition on ACE than 
epigallocatechin-3-O-gallate [58]. The results of the above mentioned study prove that structural 
modification of some flavonoids could offer a greater potential to use them as more effective 
ACE inhibitors. 
 
Comparison of IC50 Values of Flavonoids 
The IC50 values for ACE of most of reported flavonoids have summarized (Table 1). We have 
investigated  the  IC50  values  of  quercetin,  quercetin-3-glucoside,  quercetin-3-galactoside  and 
cyanidin-3-galactoside which were 151 µM, 71 µM, 180 µM, 206 µM, respectively (Balasuriya 
and Rupasinghe, unpublished). The values fall within the range of IC50 values reported for other 
flavonoid compounds. Further we investigated the ACE inhibition of some selected flavonoid 
metabolites.  Among  the  metabolites  tested  quercetin-3-glucuronic  acid  showed  successful 
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other  tested  compounds,  giving  an  IC50  value  of  27  µM.  When  compared  to  quercetin-3-
glucoside, the presence of carboxylic acid group in the glucuronide, seems to contribute to the 
inhibition of ACE.  
Some of the reported studies had focused on ACE inhibitory property of plant extracts. 
Table 2 summarizes the IC50 values of effective plant extracts on ACE inhibition. In our study, a 
flavonoid-rich apple peel extract rich in flavonoids shows an IC50 of 49 µM (Balasuriya and 
Rupasinghe, unpublished). Compared to other plant extracts reported, apple peel extract is an 
effective ACE inhibitor. When compared to all the reviewed flavonoid compounds, quercetin 
metabolites and plant extracts with the drugs (Table 3), none of the flavonoids or the extracts 
showed similar IC50 values of the drugs. It is convincing that naturally occurring flavonoids are 
not potent treatments for hypertension but could offer promise for reducing the hypertension at 
early or mid stages of the risk.  
 
Table 1: IC50 values of ACE inhibitory flavonoids and their metabolites. 
Group of 
Flavonoids 
Compound  IC50 Value  Reference 
Anthocyanins  Delphinidin-3-O-sambubioside  142 µM  [6] 
  Cyanidin-3-O-sambubioside  118 µM  [6] 
  Cyanidin-3-O-β-glucoside  139 µM  [27] 
 
Flavones  Apigenin  280 µM  [21] 
  Luteolin  290 µM  [21] 
  Luteolin-7-O-glucopyranoside  280 µM  [21] 
 
Flavonols  Quercetin glucuronide  200 µM  [60] 
  Quercetin-3-O-(6´´-galoyl)-galactoside  160 µM  [60] 
  Quercetin-3-O-α—(6-caffeoylglucosyl- 
                        β-1,2-rhamnoside) 
Quercetin-3-O-α—(6-p-   
coumaroylglucosyl-β-1,2- rhamnoside) 
Isorhamnetin-3-β-glucopyranoside 
159 µM 
 
352 µM 
 
409 µM 
[36] 
 
[36] 
 
[36] 
  Quercetin-3-β-glucopyranoside  709 µM  [36] 
  Quercetin-3-α-arabinopyranoside  310 µM  [21] 
  Kaempferol-3-α-arabinopyranoside  393 µM  [36] 
 
Flavan-3-ols 
 
Epicatechin - dimer 
 
97 µM 
 
[34] 
  Epicatechin - tetramer  4 µM  [34] Functional Foods in Health and Disease 2011; 5:172-188                                                                           Page 182 of 188 
  Epicatechin - hexamer  8 µM  [34] 
 
Chalcones 
 
Flavonoid 
metabolites 
Butein 
 
Quercetin-3-O-glucuronic acid 
730 µM 
 
27 µM 
[20] 
 
Balasuriya  and 
Rupasinghe 
(Unpublished) 
 
 
Table 2: ACE inhibition (IC50 Values) by various plant extracts  
Plant Extracts  IC50 Value  Reference 
Hibiscus sabdariffa (Hibiscus)  91 µg/mL  [6] 
Camelia synensis (green tea)  125 µg/mL  [61] 
Vaccinium ashei reade (Blueberry leaf 
extract) 
Vaccinium myrtillus (Bilberry) 
46 µg/mL 
 
Log  -2.6 
mg/mL 
[61] 
 
[28] 
Senecio inaequidens  
(A perennial herb) 
192 µg/mL  [53] 
S. ambiguous subsp. Ambigus  
(ethyl acetate extract) 
219 µg/mL  [53] 
S. ambiguous subsp. Ambigus 
(n-hexane extract) 
307 µg/mL  [53] 
Cryptomeria japonica (Japanese Cedar)  16 µg/mL  [54] 
Malus domestica 
(Apple skin ethanol extract) 
49 µg/mL  Balasuriya and Rupasinghe 
(Unpublished) 
 
 
Table 3: IC50 Values of ACE for Antihypertensive Drugs  
Drug  IC50 Value  Reference 
Captopril
®  0.02 µM  [36] 
Lisinopril
®  1.8 µM  [6] 
 
 
Enzyme Kinetic Studies 
Some of the studies have focused on finding the type of enzyme inhibition of flavonoids. All 
compounds studied were in accordance with the Michaelis-Menten theorem. Anthocyanins have 
shown  competitive  type  inhibition  over  ACE.  Delphinidin-3-O-sambubioside,  cyanidin-3-O-
sambubioside, and anthocyanin rich fractions from Hibiscus species were among the samples Functional Foods in Health and Disease 2011; 5:172-188                                                                           Page 183 of 188 
studied  [6].  In  a  kinetic  study  conducted  to  find  the  effect  of  dimmers  and  tetramers  of 
procyanidins at the presence of chloride ions on ACE had found a competitive type enzyme 
inhibition irrespective of the presence of chloride ions [34]. The dimmers and hexamers of the 
epicatechins were found to be competitive inhibitors. The inhibition over two types of substrates 
(HHL and FAPGG) was studied and no difference was observed depending on the substrate [7]. 
Most flavonoids were reported to be competitive type inhibitors meaning that they can compete 
with the substrate in binding to the active site of the enzyme. A group of condensed tannins 
(procyanidin B-5 3,3'-di-O-gallate and procyanidin C-1 3,3',3"-tri-O-gallate) isolated from Rhei 
rhizoma had shown reversible and non competitive type of inhibition over ACE. The inhibitory 
kinetic were determined using Dixon plots [59]. There is not much evidence associated with the 
enzyme kinetics of specific flavonoids compared to other types of natural ACE inhibitors like 
plant and fish peptides. To the best of our knowledge, only flavan-3-ols and anthocyanins were 
the two flavonoid groups that were found to used for the enzyme kinetics studies.  
 
Summary  
Flavonoids are one of the major groups of plant secondary metabolites, with numerous beneficial 
pharmacological properties. Their recognition as effective biomolecules had made the scientists 
to  investigate  the  potential  use  of  flavonoids  and  flavonoid-rich  extracts  as  natural  ACE 
inhibitors,  where  the  ACE  activity  is  identified  as  a  critical  factor  in  regulating  high  blood 
pressure. All most all the subcategories of flavonoids were studied on ACE inhibitory activity. 
Though  the  IC50  values  for  ACE  are  very  greater  for  flavonoids  when  compared  with 
antihypertensive drugs, the most of the flavonoids are found to be competitive inhibitors of ACE. 
Among flavonoids, flavan-3-ols and anthocyanins are effective ACE inhibitors in vitro as 
well as in animal model system. Catechins and their polymers proved to be the most effective 
ACE inhibitor in vitro. However, the results of the in vitro studies may not reflect exactly the 
outcome  of  in  vivo  studies.  Therefore,  further  studies  using  animal  models  are  required  to 
confirm  their  ACE  inhibitory  properties.  Isoflavones  are  showing  intermediary  inhibition 
towards ACE. Flavonols had proved to be less effective in vitro but in animal studies they were 
found  to  be  more  effective.  Fewer  studies  had  been  conducted  on  flavones  and  chalcones. 
Structurally modified flavonoids designed for greater absorption and bioavailability could have a 
higher potential in use as ACE inhibitors.  In terms of the mode of action, flavonoids had shown 
competitive type inhibition for ACE. 
In  conclusion,  naturally  occurring  flavonoids  have  a  potential  to  be  used  as  mild  or 
moderate  ACE  inhibitors.  As  the  IC50  values  of  flavonoids  were  higher  than  that  of  the 
prescribed drugs for hypertension, flavonoids could be used as preventative nutraceuticals over 
hypertension rather than using as therapeutic drug for hypertension. Flavonoid-derived natural 
health products could become popular among patients with mild hypertension as well as the 
patients who have adverse side effects for currently available antihypertensive drugs. Future Functional Foods in Health and Disease 2011; 5:172-188                                                                           Page 184 of 188 
research  should  also  be  focused  on  structural  modifications  of  flavonoids  and  their 
antihypertensive properties.  
 
Abbreviations: Angiotensin converting enzyme (ACE),  Hippuryl-L-histidyl-L-leucine (HHL), 
N-(3-[2-furyl]acryloyl-phenylala  glycy  L  glycine  (FAPGG),  High  performance  liquid 
chromatography (HPLC) 
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